Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder
ConclusionsImprovements in ADHD symptoms and executive function occurred with dose-optimized SHP465 MAS, regardless of baseline impairment in some aspects of sleep in adults with ADHD, with no significant differences observed as a function of sleep impairment.Clinical Trials RegistrationClinicalTrials.gov identifier —NCT00150579.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: ADHD | Amphetamine | Clinical Trials | Hyperactivity | Men | Neurology | Sleep Disorders | Sleep Medicine | Statistics | Study